Is Foghorn Therapeutics Inc. (FHTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 11.0% / 30% | 72.0% / 30% | 0.0% / 30% | 52.65% / 5% | ✗ NOT HALAL |
| DJIM | 11.0% / 33% | 72.0% / 33% | 0.0% / 33% | 52.65% / 5% | ✗ NOT HALAL |
| MSCI | 13.1% / 33% | 85.8% / 33% | 0.0% / 33% | 52.65% / 5% | ✗ NOT HALAL |
| S&P | 11.0% / 33% | 72.0% / 33% | 0.0% / 33% | 52.65% / 5% | ✗ NOT HALAL |
| FTSE | 13.1% / 33% | 85.8% / 33% | 0.0% / 50% | 52.65% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -176.5% | |
| Operating Margin | -211.9% | |
| Net Margin | -240.3% | |
| Return on Assets (ROA) | -21.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$86M |
| Free Cash Flow | -$86M |
| Total Debt | $41M |
| Current Ratio | 2.7 |
| Total Assets | $198M |
Price & Trading
| Last Close | $4.90 |
| 50-Day MA | $5.51 |
| 200-Day MA | $5.08 |
| Avg Volume | 175K |
| Beta | 3.1 |
|
52-Week Range
$2.94
| |
About Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Foghorn Therapeutics Inc. (FHTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Foghorn Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Foghorn Therapeutics Inc.'s debt ratio?
Foghorn Therapeutics Inc.'s debt ratio is 11.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.1%.
What are Foghorn Therapeutics Inc.'s key financial metrics?
Foghorn Therapeutics Inc. has a market capitalization of $264M, and revenue of $31M. The company maintains a gross margin of -176.5% and a net margin of -240.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.